Cerevel Therapeutics Hldg Inc (CERE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Operating Expenses | 447,265 | 367,848 | 220,098 | 149,116 | 83,463 |
| Operating Income | -447,265 | -367,848 | -220,098 | -149,116 | -83,463 |
| Interest Expense | 10,567 | 3,918 | 0 | 0 | 0 |
| Other Income | 25,493 | 20,415 | -5,236 | -3,050 | -44,881 |
| Pre-tax Income | -432,339 | -351,351 | -225,334 | -152,166 | -128,344 |
| Income Tax | 503 | 160 | N/A | -24 | 45 |
| Net Income Continuous | -432,842 | -351,511 | -225,334 | -152,142 | -128,389 |
| Net Income | $-432,842 | $-351,511 | $-225,334 | $-152,142 | $-128,389 |
| EPS Basic Total Ops | -2.67 | -2.32 | -1.65 | -2.01 | -2.90 |
| EPS Basic Continuous Ops | -2.67 | -2.32 | -1.65 | -2.07 | -2.90 |
| EPS Diluted Total Ops | -2.67 | -2.32 | -1.65 | -2.01 | -2.90 |
| EPS Diluted Continuous Ops | -2.67 | -2.32 | -1.65 | -2.07 | -2.90 |
| EPS Diluted Before Non-Recurring Items | -2.67 | -2.32 | -1.65 | -2.01 | N/A |
| EBITDA(a) | $-461,338 | $-369,494 | $-217,345 | $-148,719 | $-83,286 |